PetVivo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
November 14, 2023 at 03:00 pm
Share
PetVivo Holdings, Inc. reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was USD 0.207366 million compared to USD 0.22328 million a year ago. Net loss was USD 3.66 million compared to USD 2.11 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.21 a year ago. Diluted loss per share from continuing operations was USD 0.28 compared to USD 0.21 a year ago.
For the six months, sales was USD 0.324549 million compared to USD 0.281454 million a year ago. Net loss was USD 6.55 million compared to USD 4.08 million a year ago. Basic loss per share from continuing operations was USD 0.53 compared to USD 0.41 a year ago. Diluted loss per share from continuing operations was USD 0.53 compared to USD 0.41 a year ago.
PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Companyâs lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a bodyâs cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.